• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas

    3/17/26 8:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    - Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient -

    - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -

    SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in vivo CRISPR atlas. The 8 million-cell, brain-wide dataset represents the largest known causal genomics resource generated directly in living tissue.

    Unlike traditional in vitro or single-organ systems, PerturbAI's in vivo CRISPR (Perturb-seq) platform measures gene function within intact organs, capturing real biological circuitry rather than isolated cell states. Today's release establishes a new category of biological data: organism-level, circuit-resolved, causal genomics.

    "The public release of this CRISPR atlas marks a foundational change for biology," said Xin Jin, Ph.D., co-founder of PerturbAI. "For the first time, we can measure gene function directly inside intact biological systems at a massive scale. This enables systems-level understanding of disease and allows us to model and simulate therapeutic interventions before committing to expensive downstream drug development."

    PerturbAI is utilizing its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics for complex metabolic and chronic diseases.

    "Given our team's deep expertise spanning CRISPR, genomics, and machine learning, we are uniquely qualified to optimize the application of vivo CRISPR and new AI models to novel therapeutic discovery, making it more scalable, translatable and cost-efficient," said Grace Zheng, Ph.D., co-founder and CEO of PerturbAI.

    PerturbAI collaborated with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics (NASDAQ:TXG) to generate and analyze the atlas, which enables systematic evaluation of the brain genome, providing a framework to distinguish causal mechanisms from context-dependent modifiers of disease risk and progression. Specifically, the dataset maps the effects of thousands of genetic perturbations across 8 million cells spanning hundreds of bona fide neuronal cell types in the mouse brain, revealing, among other findings, that the same gene can have very different consequences depending on cell type, brain region, and biological context. An accompanying manuscript titled "Genome-scale functional mapping of the mammalian whole brain with in vivo Perturb-seq" is available in biorxiv and the dataset is accessible through PerturbAI's blog , Hugging Face and the NVIDIA AI Blueprint for Single-Cell Analysis.

    The rich representation of cell states and causal responses in this atlas makes it a powerful AI-training resource, enabling prediction across diverse cellular contexts and unlocking key insights that could dramatically accelerate the development of biological foundation models.

    PerturbAI closed an oversubscribed pre-seed round in Q3 2025, backed by leading early-stage investors with deep expertise across AI, biology, and company-building.

    About PerturbAI

    PerturbAI is an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases. By combining scalable in vivo CRISPR perturbation with AI, PerturbAI maps biological circuits directly inside intact organisms, enabling a new generation of therapeutics grounded in causal, in vivo biology. Visit www.perturb.ai for more information.

    Cision View original content:https://www.prnewswire.com/news-releases/perturbai-launches-from-stealth-unveils-the-worlds-largest-in-vivo-crispr-atlas-302715616.html

    SOURCE PerturbAI

    Get the next $TXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    12/11/2025Buy → Neutral
    Citigroup
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    9/11/2025$15.00Neutral
    Piper Sandler
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Piper Sandler initiated coverage on 10x Genomics with a new price target

    Piper Sandler initiated coverage of 10x Genomics with a rating of Neutral and set a new price target of $15.00

    9/11/25 8:40:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

    SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    3/6/26 10:16:29 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by 10x Genomics Inc.

    S-8 - 10x Genomics, Inc. (0001770787) (Filer)

    2/13/26 4:05:39 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - 10x Genomics, Inc. (0001770787) (Filer)

    2/12/26 4:09:53 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saxonov Serge gifted 2,750 shares and sold $367,097 worth of shares (16,152 units at $22.73), decreasing direct ownership by 2% to 1,200,917 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    3/4/26 4:14:12 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Saxonov Serge was granted 157,895 shares, increasing direct ownership by 15% to 1,219,819 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    3/2/26 4:24:35 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Hindson Benjamin J. was granted 88,816 shares, increasing direct ownership by 21% to 513,595 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    3/2/26 4:23:49 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas

    - Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the publ

    3/17/26 8:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

    PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10

    2/19/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

    PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

    2/12/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

    SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    10/4/24 2:14:32 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

    PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

    2/12/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    1/22/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports Third Quarter 2025 Financial Results

    PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Recent Updates Revenue was $149.0 million for the third quarter, compared to $172.9 million in the second quarter, which included $27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding the second quarter one-time license and royalty revenue.Started shipping the next-generation of Chromium Flex,

    11/6/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care

    ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

    1/10/22 8:00:00 AM ET
    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials